Eli Lilly’s Foundayo: A Dual-Action Breakthrough for Obesity and Sleep Apnea
In a significant stride for cardiometabolic health, pharmaceutical giant Eli Lilly ($LLY) has unveiled compelling positive results from two late-stage trials for its oral obesity medication, Foundayo (orforglipron). These trials demonstrate the pill’s remarkable potential to not only aid in weight management but also to significantly alleviate obstructive sleep apnea (OSA) in adults. The company is now poised to submit these groundbreaking findings to the U.S. Food and Drug Administration (FDA) by the end of 2026, potentially offering a new therapeutic avenue for millions worldwide.
Foundayo’s Efficacy: A Closer Look at the ATTAIN-OSA Program
The 52-week ATTAIN-OSA program rigorously evaluated Foundayo’s impact on the apnea-hypopnea index (AHI), the gold standard for measuring sleep apnea severity. The results, presented at the American Heart Association Scientific Sessions 2026 and published in the prestigious JAMA, underscore Foundayo’s robust performance.
Transformative Results for Non-PAP Users
For the 363 participants suffering from moderate-to-severe sleep apnea and obesity or overweight who were not utilizing positive airway pressure (PAP) therapy, Foundayo delivered impressive outcomes. The drug led to a substantial reduction in breathing interruptions by an average of 21.1 events per hour, marking a 43.8% decrease from a baseline of 50.7 events. In stark contrast, the placebo group saw only a 4.3 events per hour reduction. Crucially, 31.5% of those on Foundayo achieved either remission or a classification of mild disease, a truly transformative result.
Enhancing Outcomes for PAP Therapy Users
Foundayo also demonstrated significant benefits for the 349 participants who were already using PAP therapy. In this group, the medication reduced breathing events by 18.3 per hour, a 27.5% improvement from an average baseline of 57.6. Nearly one-fifth (19.6%) of these participants reached remission or a mild disease state, indicating Foundayo’s capacity to complement existing treatments.
Beyond Breathing: Broader Health Improvements
The benefits of Foundayo extended beyond just respiratory improvements. The trials revealed a notable reduction in sleep apnea-specific hypoxic burden, which quantifies the depth and duration of oxygen drops during sleep. Non-PAP users experienced a 55.9% reduction, while PAP users saw a 45.8% decrease. Furthermore, participants achieved an average body weight loss of 11.5% and 11.2% respectively, accompanied by an average reduction in systolic blood pressure of 8.6 mmHg and 7.3 mmHg. These systemic improvements highlight Foundayo’s potential for comprehensive cardiometabolic health benefits.
Safety Profile and Future Prospects
Eli Lilly reported that Foundayo’s safety profile remained consistent with previous trials in the ACHIEVE and ATTAIN programs. The most commonly observed adverse events were gastrointestinal, including nausea, diarrhea, constipation, dyspepsia, and vomiting, generally ranging from mild to moderate. Discontinuation rates due to adverse events were 12.2% for Foundayo users without PAP therapy (vs. 3.8% for placebo) and 6.8% for Foundayo users with PAP therapy (vs. 0.6% for placebo).
Thomas Seck, Senior Vice President of Product Development for Lilly Cardiometabolic Health, emphasized the drug’s impact: “Foundayo is already making a difference for people living with obesity, and with plans to submit these results to the FDA by the end of the year, we could have the opportunity to help people living with OSA.”
Foundayo is currently approved in the U.S. for adults with obesity, and a European Medicines Agency committee recently recommended its approval for obesity and type 2 diabetes. While Lilly’s injectable Zepbound is already approved for moderate-to-severe sleep apnea in adults with obesity, Foundayo represents a significant oral alternative. With an estimated 936 million adults globally affected by sleep apnea, many undiagnosed, Foundayo’s potential to address this widespread condition is immense, promising a new era in the management of obesity-related health challenges.
For more details, visit our website.
Source: Link
Leave a comment